poisar

Stock

Royalty Pharma plc RPRX

$68.70+0.04%

Overview

RPRX market data

Business OverviewA provider-written description of this company or fund, with its source and observation date.

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Official website

Source
massive
Observed
Cadence
Reference data reviewed periodically
Status
fresh

Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.

RPRX price chart · 1M
O
68.73
H
69.07
L
68.34
C
68.70
Vol
57,941.00

Daily history from Jun 16, 2020

Source
US equities market feed
Observed
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.

Open
$68.73
Previous Close
$68.68
Day High
$69.07
Day Low
$68.34
52 Week High
$70.10
52 Week Low
$36.91
7 Day Return
-1.49%
30 Day Return
+14.35%
90 Day Return
+13.80%
1 Year Return
+77.20%
Daily Notional Volume
$4M
Latest daily bar volume multiplied by its closing price.

Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.

Provider-backed
P/E (TTM)
58.25
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
—
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$1.37
Diluted earnings per share over the trailing twelve months.
Beta
0.37
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
3.0%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
25.7%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$37.31 – $70.37
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
—
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $39.1B · P/B 3.44 · P/S 14.95.

Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.

10 captured

Decision & ScoreThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern EvidenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer RankingThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock

AI-selected reference, checked against source evidence · Evidence observed

Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.

What business does Royalty Pharma plc operate?
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products.
Which industry is Royalty Pharma plc classified in?
The SEC company record classifies Royalty Pharma plc under Pharmaceutical Preparations. This filing classification provides industry context alongside the provider's business description.

What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.

  • Business activities described in the company reference
  • Original company disclosures and industry classification